Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Argye Hillis MD, MA
Argye Elizabeth Hillis MD, MA Associate Editor
Mark Hallett MD
Mark Hallett MD Editor-in-Chief
Nina Schor MD, PhD
Nina F. Schor MD, PhD Advisory Board
See All Experts
story of the week
Published in Neurology

Journal Scan / Research · September 12, 2024

Association Between GLP-1 Receptor Agonist Use and the Risk of Parkinson's Disease in Patients With Type 2 Diabetes

Movement Disorders: Official Journal of the Movement Disorder Society

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Susan Fox MB, ChB, MRCP(UK), PhD

Alvaro Hernandez-Guillen MD

Leila Montaser Kouhsari MD, PhD

Movement Disorders: Official Journal of the Movement Disorder Society
Glucagon-Like Peptide-1 Receptor Agonists and Risk of Parkinson's Disease in Patients with Type 2 Diabetes: A Population-Based Cohort Study
Mov. Disord. 2024 Aug 27;[EPub Ahead of Print], H Tang, Y Lu, MS Okun, WT Donahoo, A Ramirez-Zamora, F Wang, Y Huang, M Armstrong, M Svensson, BA Virnig, ST DeKosky, J Bian, J Guo

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Most Read This Week

Recently Updated